Weill Cornell Receives $3 Million to Study HIV as Trump Restructures HIV Grants
By Matteus Jasik and Lila Davis
“I’m honored that NIMH has given us the unique opportunity to move cutting-edge research forward that we hope will ultimately transform the lives and care of people with HIV,” Prof. Lishomwa Ndhlovu, immunology in medicine, a researcher at Weill Cornell and co-director of the center told the Cornell Chronicle.
Ndhlovu added that he hopes the center will close a “critical gap” in current treatment.
This is not the first collaboration between Weill and Rutgers — the schools were granted $4.5 million by the National Institutes of Health in 2021 to study HIV treatment and prevention amongst New York area patients.
Given the prior collaboration, “it felt natural to build on our strategic partnership,” Ndhlovu told the Chronicle. This funding award recognizes the “complementary expertise across Rutgers, Weill Cornell and the broader New York-New Jersey research community,” added Tricia Burdo, associate director of the Rutgers Institute for Translational Medicine and Science.
The center’s opening comes amid recent moves by the Trump administration to deprioritize HIV research and prevention.
In July, President Donald Trump slashed funds for foreign aid, resulting in over 1,700 HIV treatment sites closing worldwide. The president also proposed an 80% funding cut to a Center for Disease Control program focused on preventing the spread of HIV in his 2027 budget.
Currently incurable, HIV has led to approximately 44.2 million deaths since the start of the HIV and AIDS epidemic in 1981, according to the Joint United Nations Programme on HIV/AIDS.
The virus is transmitted through direct contact with specific bodily fluids, and was initially known to be spread amongst gay men, who are still 18 times more likely to be infected, according to UNAIDS. Researchers have developed almost 200 related drugs for treatment of the virus but are still working on a vaccine and cure.
“There are still no effective therapies that specifically prevent or mitigate ongoing brain injury,” Ndhlovu told the Chronicle. He added that the team plans to apply for additional funding to transform the program into an expansive care center for the region.
The center’s development also follows recent changes in the NIH which deprioritize research surrounding HIV.
In October, the NIH called for four large HIV research programs to temporarily hold off on new studies, according to The New York Times.
And, in January 2026, the NIH announced an end to its grant application cycle for AIDS-specific research, originally created to speed up funding during the HIV/AIDS epidemic. Applicants seeking funding for HIV-related projects must compete with all applications for NIH funding going forward.
Ndhlovu wrote in a statement to The Sun that it is “too soon” to know the impacts of the NIH funding schedule change on HIV research.
The Cornell and Rutgers research team pursued funding through an alternative agency, the NIMH, avoiding the NIH grant application process.
Prof. William Lodge II, public policy, noted that the NIH’s stance on HIV research has been uncertain under the Trump administration. Research funding has been “given back, and then cut, and then given back,” he said.
Alongside his proposed cuts to the CDC program’s budget and removal of other HIV funding, the Trump administration reversed an initial $2 billion cut in funding to the Department of Human Health and Services’ addiction and mental health programs in January, which also provides HIV prevention programs.
Trump previously pledged to fight HIV during his first term in office.
In the 2019 State of the Union Address, Trump committed to ending the HIV/AIDS epidemic in the U.S. by 2030, stating that “together, we will defeat AIDS in America.” With this, he launched the Ending the HIV Epidemic in the U.S., which focuses HIV resources in the areas they are needed most.
Lodge also pointed to rules that restrict research on gender as potentially limiting the subject matter of studies regarding HIV.
The Trump administration proposed new rules restricting funding from research on “wokeness,” “gender ideology” and “diversity” in May 2026. These rules were set to go into effect on Oct. 1, but Congress extended all current funding and effectively deferred the new rules until Dec. 11.
Trump also signed an Executive Order in 2025 stating that the United States government only recognizes the male and female genders and that these “sexes are not changeable.”
“If NIH and the United States government doesn’t recognize transgender women or trans individuals as a gender, then that means funding and applying for [HIV funding] is actually much harder,” Lodge said. This “ultimately undermin[es] [researchers] ability to advance health equity in HIV research and address the needs of populations disproportionately affected by HIV.”
Amid uncertainty regarding the future of HIV research under the Trump administration, “there’s still some settling of the waters,” leaving a sense that there is “a black box on what's actually going on,” remarked Lodge.
“Under President Trump and Secretary Kennedy’s leadership, NIH remains focused on rigorous, gold-standard research that delivers meaningful results for the American people, including continued investment in HIV research,” a spokesperson for the NIH wrote to The Sun.
Weill Cornell did not respond to a request for comment.
Lila Davis
Lila Davis is a member of the Class of 2029 in the College of Agriculture and Life Sciences. She is a staff writer for the news department and can be reached at ldavis@cornellsun.com.
Contact:
Sophia Dasser '28
Editor in Chief | The Cornell Daily Sun
Cell: 321-203-6550
Source: The Cornell Daily Sun
https://www.cornellsun.com/article/2026/11/weill-cornell-receives-3-million-to-study-hiv-as-trump-restructures-hiv-grants
“Reproduced with permission - The Cornell Daily Sun”
The Cornell Daily Sun
Back to…
Positively Positive - Living with HIV/AIDS: HIV/AIDS News
For more HIV and AIDS News visit…
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
|